As of December 31, 2012, TearLab had $15.4 million in cash and cash equivalents.
"As demonstrated by our system order volumes for the fourth quarter, we had a very strong showing at the American Academy of Ophthalmology ("AAO") annual meeting in November," commented Elias Vamvakas, TearLab's Chief Executive Officer. "To help put that in perspective, 45% of total 2012 system orders came in the fourth quarter alone. While that sales performance was not fully reflected in our Q4-2012 financial results due to the lag between contract signing and product shipment, it is clear that we are starting to build a substantial recurring revenue base for the future."
Mr. Vamvakas continued, "Now, despite the absence of large events like AAO, growing doctor interest in our technology and the significant role that it can play in the objective diagnoses and management of Dry Eye Disease has continued to drive positive momentum in the first quarter of 2013. Moving forward, we plan on continuing to execute our marketing strategy and to build our sales organization in order to help the groundbreaking TearLab® Osmolarity test grow to its full potential."
Conference Call and Webcast InformationTearLab will hold a conference call to discuss these results today, March 20, at 8:30am Eastern Time at 877-303-1593. The call will also be broadcast live and archived on TearLab's website at www.tearlab.com under the "webcasts" link in the Investor Relations section. For those wishing to listen to a recording of the call via telephone, a replay will be made available as soon as possible after the conclusion of the live call and will remain posted for a period of seven days. To listen to the recording, simply telephone (Toll free) 855-859-2056 or (Toll) 404-537-3406 and enter reservation #14510627 when prompted. About TearLab Corporation TearLab Corporation ( www.tearlab.com) develops and markets lab-on-a-chip technologies that enable eye care practitioners to improve standard of care by objectively and quantitatively testing for disease markers in tears at the point-of-care. The TearLab Osmolarity Test, for diagnosing Dry Eye Disease, is the first assay developed for the award-winning TearLab Osmolarity System. Headquartered in San Diego, CA, TearLab Corporation's common shares trade on the NASDAQ Capital Market under the symbol 'TEAR' and on the Toronto Stock Exchange under the symbol 'TLB'. Forward-Looking Statements This press release may contain forward-looking statements. These statements relate to future events and are subject to risks, uncertainties and assumptions about TearLab. Examples of forward-looking statements in this press release include statements regarding our future recurring revenue expectations and our plans for executing our marketing strategy and building a salesforce, the future potential of the TearLab ® Osmolarity System and the related impact on our sales. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. Many factors may cause our actual results to differ materially from any forward-looking statement, including the factors detailed in our filings with the Securities and Exchange Commission and Canadian securities regulatory authorities, including but not limited to our annual and quarterly reports on Forms 10-K and 10-Q. We do not undertake to update any forward-looking statements.
|CONSOLIDATED STATEMENTS OF OPERATIONS (expressed in U.S. dollars except number of shares) ($ 000's)|
|Three months ended December 31||Year ended December 31|
|Revenue||$ 1,610||$ 499||$ 3,960||$ 2,124|
|Cost of goods sold||930||409||2,295||1,626|
|Amortization of intangible assets||304||304||1,215||1,215|
|General and administrative||1,140||1,100||4,770||3,842|
|Clinical, regulatory and research & development||618||542||2,241||1,304|
|Sales and marketing||1,942||865||5,471||2,195|
|Total operating expenses||4,004||2,811||13,697||8,556|
|Loss from operations||(3,324)||(2,721)||(12,032)||(8,058)|
|Other income (expenses)||(328)||(751)||(7,280)||(751)|
|Weighted average number of shares outstanding – basic and diluted||28,607,209||20,414,993||25,490,186||17,744,736|
|Net loss per common share – basic and diluted||$ (0.13)||$ (0.17)||$ (0.76)||$ (0.50)|
|CONSOLIDATED BALANCE SHEETS (expressed in U.S. dollars) ( $ 000's)|
|December 31, 2012||December 31, 2011|
|Cash and cash equivalents||$ 15,437||$ 2,807|
|Accounts receivable, net||889||321|
|Other current assets||60||35|
|Total current assets||18,636||4,251|
|Fixed assets, net||630||199|
|Patents and trademarks, net||136||164|
|Intangible assets, net||4,709||5,924|
|Other non-current assets||28||—|
|Total assets||$ 24,139||$ 10,538|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Accounts payable||$ 1,067||$ 218|
|Obligations under warrants||6,239||2,957|
|Total current liabilities||9,295||5,018|
|Preferred Stock, $0.001 par value, 10,000,000 authorized none outstanding||—||—|
|Common stock, $0.001 par value, 65,000,000 authorized, 28,741,653 issued and outstanding at December 31, 2012 and 40,000,000 authorized, 20,414,993 issued and outstanding at December 31, 2011||29||20|
|Additional paid-in capital||421,662||393,035|
|Total stockholders' equity||14,844||5,520|
|Total liabilities and stockholders' equity||$ 24,139||$ 10,538|
CONTACT: Investors: Stephen Kilmer (905) 906-6908 email@example.com Media: Leonard Zehr Managing Director Kilmer Lucas Inc. (905) 486-1158 firstname.lastname@example.org
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV